Figure 3From: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitorsPercentage of patients responding to a second TNF-α inhibitor by reason for discontinuation of first. Bar graph showing the percentage of patients achieving a response to a second tumor necrosis factor (TNF)-α inhibitor according to criteria commonly used in rheumatoid arthritis by reason of discontinuation of the initial TNF-α inhibitor. ACR, American College of Rheumatology (see Figure 1 legend for description of ACR20, ACR50 and ACR 70 criteria); DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism.Back to article page